WS
RNTX

Wedbush Securities’s Rein Therapeutics RNTX Stock Holding History

Wedbush Securities’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,750
Closed -$45K – 993
2020
Q3 		$45K Buy
+1,750
New +$41.2K ﹤0.01% 893

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Wedbush Securities's RNTX Position: Q4 2020 in Review

Wedbush Securities sold out of Rein Therapeutics (RNTX) in Q4 2020, closing a stake of 1,750 shares — an estimated $45K sold.

Wedbush Securities first reported a position in RNTX in Q3 2020 and held it in 1 quarter. The position peaked at $45K in Q3 2020. 30 funds tracked by Wall St. Rank hold RNTX as of Q4 2020.

  • Wedbush Securities reported no remaining Rein Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 1,750 Rein Therapeutics shares in Q4 2020, an estimated $45K.
  • Wedbush Securities first reported a position in Rein Therapeutics in Q3 2020 and held it in 1 quarter.
  • Wedbush Securities's Rein Therapeutics position peaked at $45K in Q3 2020.
  • 30 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.